Dabigatran etexilate and reduction in serum apolipoprotein B

Genetic and Pharmacological Modifications of Thrombin Formation in Apolipoprotein E-deficient Mice Determine Atherosclerosis Severity and Atherothrombosis Onset in a Neutrophil-Dependent Manner

(2013) Julian I. Borissoff et al.   PLoS One

Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease

(2012) Karen M. Kassel et al.   AMERICAN JOURNAL OF PATHOLOGY

The Beneficial Effects of a Direct Thrombin Inhibitor, Dabigatran Etexilate, on the Development and Stability of Atherosclerotic Lesions in Apolipoprotein E-deficient Mice

(2012) Nikolaos P. E. Kadoglou et al.   CARDIOVASCULAR DRUGS AND THERAPY

Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins

(2012) S. Matthijs Boekholdt et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dabigatran etexilate: A novel oral direct thrombin inhibitor

(2011) M. L. Blommel et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

(2011) John A. Cairns et al.   CANADIAN JOURNAL OF CARDIOLOGY

A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk

(2011) Allan D. Sniderman et al.  

Pharmacological basis and clinical evidence of dabigatran therapy

(2011) Santiago Redondo et al.   Journal of Hematology & Oncology

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk

(2011) Terry A. Jacobson   MAYO CLINIC PROCEEDINGS

Loss of TGH/Ces3 in Mice Decreases Blood Lipids, Improves Glucose Tolerance, and Increases Energy Expenditure

(2010) Enhui Wei et al.   Cell Metabolism

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study

(2010) Martin J O'Donnell et al.   LANCET

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population

(2008) J. Sierra-Johnson et al.   EUROPEAN HEART JOURNAL

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

(2008) Matthew J McQueen et al.   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE